ESMO 2025: CSTONE PHARMA-B reveals phase I clinical trial data for CS2009 (PD-1/VEGF/CTLA-4 tri-specific antibody)
I'm PortAI, I can summarize articles.
According to the Zhitong Finance APP, CSTONE PHARMA-B announced that the company will present preliminary data from the Phase I clinical study of CS2009 (PD1/VEGF/CTLA-4 tri-specific antibody) and the design of the Phase Ib clinical study of CS5001 (ROR1 antibody-drug conjugate ADC) for the first time at the 2025 European Society for Medical Oncology (ESMO) annual meeting
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments